Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Early differentiation between Mycobacterium tuberculosis (MTB) and non-tuberculous mycobacteria (NTM) is critical due to distinct treatment protocols. Traditional diagnostic methods, including acid-fast staining, bacterial culture, and nucleic acid assays, often face challenges. This study evaluated the diagnostic value of Guanylate-Binding Protein 1 (GBP1), interferon-gamma (IFN-γ), and interleukin-2 (IL-2) in peripheral blood for distinguishing active TB, NTM infections, and cured TB.
Methods: We recruited patients with active TB (n = 50), NTM disease (n = 46), cured TB (n = 37), and healthy controls (HC, n = 20). GBP1 mRNA in peripheral blood mononuclear cells was quantified by qPCR. MTB-specific IFN-γ and IL-2 levels were measured by ELISA.
Results: The relative expression of GBP1 was significantly higher in active TB (2.764 ± 1.774) and in NTM patients (2.099 ± 0.665) compared to healthy control group (-0.001 ± 1.844; P < 0.0001 and P < 0.01, respectively). Additionally, IL-2 showed prognostic value, as levels in cured TB patients (135.7 ± 332.9) were significantly lower than in active TB patients (362.7 ± 530.7, P < 0.01). For differentiating active TB from healthy controls, the area under the receiver operating characteristic curve (AUC) for GBP1 was 0.899, outperforming IFN-γ (0.846) and IL-2 (0.786). Crucially, a combined three-marker panel demonstrated superior diagnostic performance in all comparisons, notably achieving an AUC of 0.990 for distinguishing active TB from NTM disease, significantly higher than any single marker.
Conclusions: GBP1 is a robust marker for identifying mycobacterial infections (both MTB and NTM). While IL-2 shows potential for monitoring treatment response, the combined detection of GBP1, IFN-γ, and IL-2 provides the highest diagnostic accuracy, effectively differentiating between NTM and MTB infections. This panel offers a promising tool for improving clinical diagnosis and patient management.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cca.2025.120565 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
FcRγ-dependent NK cell licensing through CD244 promotes antitumour immunity.
Cancer Immunol Res
September 2025
QIMR Berghofer Medical Research Institute, Herston, QLD, Australia.
Natural killer (NK) cell licensing is an educational process that enhances responsiveness to activating signals in maturing NK cells and is predominantly regulated by major histocompatibility complex (MHC) class I-specific inhibitory signals. However, the role of non-MHC signalling in this process remains unclear. Here, we investigated the role of FcRγ, an adaptor protein associated with activating receptors, in the regulation of NK cell responsiveness.
View Article and Find Full Text PDFComments on: Increased serum soluble interleukin-2 receptor concentrations are linked to high-sensitivity troponin T and disease progression in systemic sclerosis.
Clin Exp Rheumatol
September 2025
Department of Rheumatology and Immunology, Sichuan Tianfu New Area People's Hospital, Chengdu, Sichuan, China.
Reply to the comments on: Increased serum soluble interleukin-2 receptor concentrations are linked to high-sensitivity troponin T and disease progression in systemic sclerosis.
Clin Exp Rheumatol
September 2025
Department of Rheumatology and Clinical Immunology, University of Lübeck, Germany.
Impact of Serum/Xeno-Free Medium and Cytokine Supplementation on CAR-T Cell Therapy Manufacturing in Stirred Tank Bioreactors.
Biotechnol J
September 2025
Department of Biochemical Engineering, University College London, London, UK.
Chimeric antigen receptor T-cell (CAR-T) therapies have demonstrated clinical efficacy in treating haematological malignancies, resulting in multiple regulatory approvals. However, there is a need for robust manufacturing platforms and the use of GMP-aligned reagents to meet the clinical and commercial demands. This study investigates the impact of serum/xeno-free medium (SXFM) and cytokine supplementation on CAR-T cell production in static and agitated culture systems, using 24-well plate G-Rex vessels and 500 mL stirred tank bioreactors (STRs), respectively.
View Article and Find Full Text PDFPro- and Anti-Inflammatory Responses and Clinical Outcomes in Critically Ill Patients With Endotheliopathy: A Cohort Study.
Acta Anaesthesiol Scand
October 2025
Centre for Anaesthesiological Research, Department of Anaesthesiology, Zealand University Hospital, Køge, Denmark.
Background: Multiple organ dysfunction syndrome (MODS) in critical illness involves dysregulated immune and inflammatory responses, endotheliopathy, and coagulation activation. We investigated how three types of endotheliopathy biomarkers relate to pro- and anti-inflammatory responses and clinical outcomes in intensive care unit (ICU) patients.
Methods: In this secondary, explorative analysis of a prospective single-centre cohort (n = 459), we assessed associations between endotheliopathy biomarkers (syndecan-1, soluble thrombomodulin (sTM), platelet endothelial cell adhesion molecule-1 (PECAM-1)) and inflammatory biomarkers (pro-inflammatory: IFN-ϒ, IL-1β, IL-2, IL-6, IL-8, IL-12p70, TNF-α; anti-inflammatory: IL-4, IL-10, IL-13) at ICU admission using linear regression.